A 63.1% objective response rate across 65 efficacy-evaluable patients with previously untreated stage 4 non-small cell lung cancer is a number that demands attention, and Eikon Therapeutics put it on the table at the 2026 ESMO Congress in Madrid on October 26. The data come from TeLuRide-005, an open-label Phase 2 trial testing EIK1001, a TLR7/8 dual-agonist, added on top of pembrolizumab and histology-appropriate chemotherapy. The 89.2% disease control rate at a median follow-up of 17.2 months suggests the responses are not fleeting, and they appeared across all PD-L1 tumor proportion score subgroups, meaning the drug did not simply reward patients already predisposed to respond to checkpoint blockade.
The histology split tells the more interesting story. Among the 29 squamous patients, the ORR reached 72.4% with a 100% disease control rate and a median duration of response of 12.9 months at a median follow-up of 12.7 months. The 36 non-squamous patients showed a lower ORR of 55.6% and a DCR of 80.6% at a longer follow-up of 17.9 months, with a median duration of response of 11.2 months. The squamous signal drew attention given that subtype’s traditionally challenging treatment landscape.
The tolerability data matter as much as the efficacy numbers, because earlier TLR7/8 programs have faced challenges with cytokine release syndrome and systemic toxicity, and Eikon frames outpatient administration as a potential differentiator from those prior agents. In TeLuRide-005, all seven cytokine release syndrome events were low-grade (five Grade 1, two Grade 2), with no Grade 3 or higher events and no treatment-related deaths. Grade 3 or higher treatment-related adverse events occurred in 48.6% of participants, driven mostly by neutropenia at 30.6%, and only 6.9% discontinued due to treatment-related adverse events. That profile allowed outpatient administration throughout the trial, which Eikon frames as a potential differentiator from earlier TLR7/8 agents.
Eikon is already running a Phase 2/3 registrational trial called TeLuRide-008 in the same first-line stage 4 NSCLC population. The company expects a first interim analysis in the second half of 2027 to select the single EIK1001 dose carried into the remainder of that trial. That dose-selection readout is the number to watch: it will determine whether the efficacy and tolerability seen in TeLuRide-005 can be locked to a specific dose before the pivotal portion of the study runs.
Source link: https://www.sec.gov/Archives/edgar/data/1861123/000119312526430860/eikn-20261026.htm
EIK1001: the facts in one place
- Also written: resiquimod sulfate
- Sponsor: Eikon Therapeutics
- Mechanism: systemically administered dual agonist of Toll-like receptors 7 and 8
- Indication studied: previously untreated stage 4 non-small cell lung cancer (NSCLC)
- Phase: Phase 2 (TeLuRide-005); Phase 2/3 (TeLuRide-008)
- Enrollment: 72
- Primary endpoint: safety and tolerability
- Headline result: 63.1% objective response rate and 89.2% disease control rate in 65 efficacy-evaluable patients in TeLuRide-005
- Registry identifier: NCT06246110, NCT07365319
- Current status: TeLuRide-005 completed enrollment Q1 2026; TeLuRide-008 dosed first patient July 27, 2026, with interim dose-selection analysis anticipated second half of 2027
- TeLuRide-005 enrollment completed: Q1 2026
- TeLuRide-008 first patient dosed: July 27, 2026
- Updated TeLuRide-005 data presented at ESMO Congress: October 26, 2026
- NCT06246110 last updated on ClinicalTrials.gov: May 28, 2026
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
